Enhanced evoked excitatory transmitter release in experimental neuropathy requires descending facilitation

J Neurosci. 2003 Sep 10;23(23):8370-9. doi: 10.1523/JNEUROSCI.23-23-08370.2003.

Abstract

Nerve injury-induced afferent discharge is thought to elicit spinal sensitization and consequent abnormal pain. Experimental neuropathic pain, however, also depends on central changes, including descending facilitation arising from the rostral ventromedial medulla (RVM) and upregulation of spinal dynorphin. A possible intersection of these influences at the spinal level was explored by measuring evoked, excitatory transmitter release in tissues taken from nerve-injured animals with or without previous manipulation of descending modulatory systems. Spinal nerve ligation (SNL) produced expected tactile and thermal hyperesthesias. Capsaicin-evoked calcitonin gene-related peptide (CGRP) release was markedly enhanced in lumbar spinal tissue from SNL rats when compared with sham-operated controls. Enhanced, evoked CGRP release from SNL rats was blocked by anti-dynorphin A(1-13) antiserum; this treatment did not alter evoked release in tissues from sham-operated rats. Dorsolateral funiculus lesion (DLF) or destruction of RVM neurons expressing mu-opioid receptors with dermorphin-saporin, blocked tactile and thermal hypersensitivity, as well as SNL-induced upregulation of spinal dynorphin. Spinal tissues from these DLF-lesioned or dermorphin-saporin-treated SNL rats did not exhibit enhanced capsaicin-evoked CGRP-IR release. These data demonstrate exaggerated release of excitatory transmitter from primary afferents after injury to peripheral nerves, supporting the likely importance of increased afferent input as a driving force of neuropathic pain. The data also show that modulatory influences of descending facilitation are required for enhanced evoked transmitter release after nerve injury. Thus, convergence of descending modulation, spinal plasticity, and afferent drive in the nerve-injured state reveals a mechanism by which some aspects of nerve injury-induced hyperesthesias may occur.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Afferent Pathways / metabolism
  • Afferent Pathways / physiopathology*
  • Analgesics, Opioid / pharmacology
  • Animals
  • Calcitonin Gene-Related Peptide / metabolism
  • Capsaicin / pharmacology
  • Disease Models, Animal
  • Dynorphins / metabolism
  • Enkephalins / metabolism
  • Hyperesthesia / etiology
  • Hyperesthesia / physiopathology
  • Ligation
  • Lumbosacral Region
  • Male
  • Medulla Oblongata / drug effects
  • Medulla Oblongata / physiopathology
  • Microinjections
  • N-Glycosyl Hydrolases
  • Nerve Compression Syndromes / complications
  • Nerve Compression Syndromes / physiopathology*
  • Neuralgia / etiology
  • Neuralgia / physiopathology*
  • Neuronal Plasticity
  • Neurotransmitter Agents / metabolism*
  • Oligopeptides / pharmacology
  • Opioid Peptides
  • Pain Measurement / drug effects
  • Protein Precursors / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Opioid, mu / drug effects
  • Receptors, Opioid, mu / metabolism
  • Recombinant Fusion Proteins / pharmacology
  • Ribosome Inactivating Proteins, Type 1
  • Saporins
  • Sensory Thresholds / drug effects
  • Spinal Cord / drug effects
  • Spinal Cord / metabolism
  • Spinal Cord / physiopathology
  • Spinal Nerves / metabolism
  • Spinal Nerves / physiopathology*

Substances

  • Analgesics, Opioid
  • Enkephalins
  • Neurotransmitter Agents
  • Oligopeptides
  • Opioid Peptides
  • Protein Precursors
  • Receptors, Opioid, mu
  • Recombinant Fusion Proteins
  • Ribosome Inactivating Proteins, Type 1
  • dermorphin-saporin
  • dermorphin
  • Dynorphins
  • preproenkephalin
  • N-Glycosyl Hydrolases
  • Saporins
  • Calcitonin Gene-Related Peptide
  • Capsaicin